Dr. Rafael Rosell to lead the lung cancer unit at Hospital Quirón Teknon
The Dr. Rosell Oncology Institute (IOR), led by Dr. Rafael Rosell, will begin operations at the Teknon Oncology Institute (IOT) this October. IOT is a leader in the fields of radiation oncology, hemato-oncology and medical oncology, with specialized treatment units for different tumor types. The renowned oncologist joins the team to lead the lung cancer unit.
Thus IOR and IOT join forces to offer comprehensive, innovative lung cancer treatment, including genetic diagnosis and liquid biopsy, as well as developing new lines of research through clinical trials.
Teknon is the fourth hospital from the Quirónsalud Group – joining Dexeus, Sagrat Cor and General de Catalunya – to incorporate the precision oncology services offered by IOR, the diagnosis and treatment division of Pangaea.
Barcelona, September 28 – Hospital Quirón Teknon - Quirónsalud Group - and the Dr. Rosell Oncology Institute (IOR), the diagnosis and treatment arm of Pangaea, have signed a strategic agreement to provide lung cancer patients with precision oncology treatment and develop new lines of research in this disease. Both Teknon and IOR are leaders in healthcare services delivery, cancer diagnostics & treatment and investigation. Both are focused on establishing new synergies in oncology, particularly lung cancer.
The team led by Dr. Rafael Rosell, world leader in oncology and head of IOR, will begin operations at the Teknon Oncology Institute (IOT) in October of this year. Founded in 2000, IOT is dedicated to the diagnosis and treatment of cancer patients and is a leader in the fields of radiation oncology, hemato-oncology and medical oncology, boasting dedicated treatment units for different tumor types, such as breast, gastrointestinal, genitourinary, gynecology, dermatology and lung, among others, with related tumor committees. Dr. Rosell joins the team to lead the lung cancer unit.
With this agreement the Quirónsalud Group and Pangaea add a fourth hospital to their alliance to deliver personalized cancer diagnostics and treatment. These services are already on offer through three other hospitals owned by the Group in Catalonia: Dexeus, Sagrat Cor and Hospital General de Catalunya.
Dr. Jose Luis Simon Riazuelo, director of Hospital Quirón Teknon, believes that with this alliance "We gain a renowned and prestigious leader in the field of lung cancer, improve our offering in the area of personalized oncology and increase our participation in clinical trials by bringing both entities together and involving world-renowned oncologists and teams of professionals."
Javier Rivela, CEO of Pangaea, adds that "Teknon is one of the greatest centers of medical excellence in the entire Quirónsalud group. This agreement represents another step in our strategic agreement with Quirónsalud. Thus we make the most of capabilities of both parties and place the combined experience of our treatment division, the Dr. Rosell Oncology Institute, in the areas of molecular diagnostics, clinical trials and precision oncology at the service of lung cancer patients."
Dr. Rafael Rosell, Chief Medical Officer and President of IOR, believes that "Thanks to this agreement with Teknon we can now reach even more patients with lung cancer. Despite progress in recent years with the use of targeted drugs, lung cancer remains one of the most difficult tumors to treat. However, it is one of those with the highest number of known genomic alterations and detecting these allows us to customize treatment and improve the prospects and survival of these patients."
Dr. Rafael Rosell, MD, PhD, is Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Badalona (ICO), Chief Medical Officer and President of the Dr. Rosell Oncology Institute, President and Scientific Director of Pangaea and Founder Member of the ETOP (European Thoracic Oncology Platform). His numerous contributions to medical and translational oncology, with special emphasis on the field of non-small cell lung cancer, have earned him international recognition: in 2013 he was recognized by the British journal The Lancet as the highest authority in lung cancer in Europe, and has received numerous awards in recognition of his tireless research into the causes and treatment of cancer.
Pangaea Biotech S.L is a biotechnology company led by renowned oncologist Dr. Rafael Rosell. Founded in 2007, Pangaea has three areas of activity: diagnostic services and development of new diagnostic tools, with special focus on liquid biopsy; development of new anticancer drugs; patient treatment through the Dr. Rosell Oncology Institute (IOR). Pangaea currently has agreements in place to deliver oncology services at the Sagrat Cor & Dexeus (Barcelona), and the General de Catalunya (Sant Cugat del Valles) university hospitals, all part of the Quirónsalud Group. Both Pangaea as IOR are highly experienced in the field of clinical trials and have a dedicated Clinical Trials Unit as well as a broad portfolio of molecular tests and pathologic diagnostics. Pangaea is also a reference laboratory in its field, boasting clients among some the largest pharmaceutical, diagnostic and biotechnology companies in the world.
Quirónsalud is the largest hospital group in Spain and the third largest in Europe. It offers hospitals in 13 autonomous communities, cutting-edge technologies and more than 6,200 beds in over 80 centers (such as Jimenez Diaz Foundation, Ruber, Hospital La Luz, Teknon, Dexeus, Polyclinic Gipuzkoa, etc.) and a large team of highly specialized, world-renowned professionals.
Quirónsalud promotes teaching activities (seven of its hospitals are university hospitals), as well as medical and scientific research (the team includes the FJD Health Research Institute, a unique private research center accredited by the Ministry of Research, Development and Innovation).
In addition, its healthcare service is organized into units and transversal networks that allow it to make the most of the combined experience of our centers, and translate research in the lab to the clinic. Currently, Quirónsalud is working on more than 1,600 research projects throughout Spain, with many of its centers performing groundbreaking research as pioneers in different specialties such as cardiology, endocrinology, gynecology, neurology and oncology, among others.